Mechanisms Within the Autonomic Nervous SysTEm undeRlying MusIc Therapy's aNalgesic Effects in Sickle Cell Disease (MASTERMIND)
Sickle Cell Disease
What this study involves
The registry does not currently label this study as recruiting. Ask about its status before planning a screening visit.
- Study type
- Interventional
- Phase
- Not applicable
- Age range
- 18 years - Not specified
- Sex eligible
- All sexes
- Healthy volunteers
- Not accepted
- Participants
- 10 Estimated
These are starting points, not an eligibility decision. The research team must review the full requirements.
About the research
Sickle cell disease causes very painful episodes that can happen without warning. Pain is one of the biggest problems for people with SCD. Medicines like opioids can help, but they have serious side effects. Doctors are looking for other ways to treat pain.
Investigators have already found that music therapy - breathing exercises guided by a trained music therapist - can lower pain in adults with SCD. But investigators don't know exactly how it works yet inside the body.
This study will look at two possible reasons why music therapy helps:
- It may calm the body's "fight-or-flight" (sympathetic) nervous system, which can make pain worse when it is too active.
- It may boost the "calming" (parasympathetic) nervous system, which may ease pain and reduce inflammation.
- It may lower swelling and inflammation in the body, which also drives pain.
Who may be able to participate?
The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.
Inclusion Criteria:
- (1) are age ≥18 years
- (2) have a diagnosis of SCD documented in the electronic health record (EHR)--- (3) meet Analgesic, Anesthetic, and Addiction Clinical Trial Translations Innovations Opportunities and Networks-American Pain Society Pain Taxonomy (AAPT) criteria for chronic SCD pain
- (4) are able to speak and understand English
- (5) have an email address and access to a mobile device with a functioning data plan (to get pain diaries)
- (6) report that pain interfered with daily activities at least 1-2 days in past week will be eligible for the study. -
Exclusion Criteria:
- (1) have \< 3 vaso-occlusive crises (VOCs) per year and no VOCs in the past 3 months
- (2) have significant visual, hearing, psychiatric or cognitive impairment
- (3) are currently engaged in mind-body therapies under the supervision of a healthcare professional specifically for pain management
- (4) have a planned major medical event in next 8 weeks (e.g., childbirth, orthopedic surgery, gene therapy, stem cell transplant) that does not include routine disease modifying therapies (e.g., blood transfusions)
- (5) are unable or unwilling to refrain from stopping all medications that interfere with the autonomic nervous system for 5 half-lives prior to autonomic testing and from changing their medication regimen during the 2 weeks that separate autonomic testings and blood draws
- (6) develop active VOC requiring hospitalization at enrollment
- (7) have conditions that would significantly affect autonomic testing interpretation, such as severe arrhythmias or pregnancy, will be excluded from the study.
Treatment, groups and participation
The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.
- Assignment
- Not applicable
- Masking
- No masking
Music Therapy
The MT-BC will engage the participant in a 20-minute deep breathing exercise with live music beating at a defined tempo. Participants will repeat this session on their own.
Behavioral: Music Therapy
Music Therapy BEHAVIORAL
Participants will undergo a 20-minute music therapy session with a board certified music therapist, then will repeat this on their own once daily for 2 weeks.
What researchers are measuring
Outcome measures describe what is being studied. They are not proof that a treatment works.
Primary measures
Change in electrodermal activity (EDA) as measured by change in electrical potential at the surface of the skin
Time frame: Baseline and after 2 weeks
Lower EDA reflects less sympathetic tone
Change in Quantitative Sudomotor Axon Reflex Test (QSART) as measured by sweat output values
Time frame: Baseline and after 2 weeks
Lower QSART values reflect less sympathetic activity
Changes in Pupillometry parameters as measured by constriction velocity
Time frame: Baseline and after 2 weeks
Faster constriction velocity indicates a higher pupillary vagal tone.
Changes in Pupillometry parameters as measured by percent reflex amplitude
Time frame: Baseline and after 2 weeks
Larger percentage of reflex amplitude indicates higher pupillary vagal tone.
Changes in Pupillometry parameters as measured by dilation velocity.
Time frame: Baseline and after 2 weeks.
Slower dilation velocity indicates lower pupillary sympathetic tone.
Change in Heart Rate Response to deep breathing
Time frame: Baseline and after 2 weeks
Increased heart rate response to deep breathing denotes increased cardiovagal tone.
Measurement of average supine resting Blood Pressure (BP)
Time frame: Baseline and after 2 weeks
Lower average resting BP denote lower cardiac sympathetic tone
Measurement of average supine resting Heart Rate (HR)
Time frame: Baseline and after 2 weeks
Lower average resting HR denote lower cardiac sympathetic tone
Change in supine resting respiratory rate
Time frame: Baseline and after 2 weeks
A lower resting respiratory rate reflects a shift of autonomic balance toward parasympathetic (vagal) dominance with reduced central sympathetic outflow.
Change in the maximum heart rate during the Valsalva maneuver
Time frame: Baseline and after 2 weeks
An increased Valsalva Ratio (maximum heart rate to the minimum heart rate) reflects an increase in cardiac parasympathetic tone.
Change in the minimum heart rate shortly after the Valsalva maneuver
Time frame: Baseline and after 2 weeks
An increased Valsalva Ratio (maximum heart rate to the minimum heart rate) reflects an increase in cardiac parasympathetic tone.
Secondary measures
Change in C Reactive Protein as measured by bloodwork
Time frame: Baseline and after 2 weeks
Lower levels of CRP indicate lower levels of inflammation
Change in Cytokine levels as measured by bloodwork
Time frame: Baseline and after 2 weeks
Lower levels of cytokines indicate lower levels of inflammation
Other measures
Pain intensity changes as measured by the Visual Analog Scale (VAS)
Time frame: Baseline and after 2 weeks of daily music therapy
The VAS is a straight 100 mm line-usually horizontal-with descriptive word anchors at each end representing opposite extremes of a subjective experience, such as 0 being "no pain" and 10 being "worst possible pain".
Pain intensity changes as measured by the Brief Pain Inventory (BPI)
Time frame: Baseline and after 2 weeks of daily music therapy
Brief Pain Inventory (BPI) is a self-administered questionnaire used to evaluate pain severity and how pain interferes with daily life on scales from 0 to 10, with 0 being no pain, and 10 being severe pain.
Pain diaries
Time frame: Daily for 2 weeks
Daily pain intensity and analgesic use
Music therapy adherence
Time frame: Daily for 2 weeks
Daily log of adherence to the home-based music therapy protocol
Review the complete result tables and limitations in the official record.
Open official results ↗Research locations (1)
The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.
1 locations
University HospitalsCleveland, Ohio, United StatesStatus unknown
Study team and timeline
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Study start
- Jan 2, 2027 Estimated
- Primary completion
- Jun 30, 2028 Estimated
- Study completion
- Jun 30, 2028 Estimated
- First posted
- Nov 10, 2026 Actual
- Last updated
- Nov 10, 2026 Actual
Official study contacts
Official study title
Mechanisms Within the Autonomic Nervous SysTEm undeRlying MusIc Therapy's aNalgesic Effects in Sickle Cell Disease (MASTERMIND)
Ask Wellness Clinical Research
Your message goes to WCR, including when this study is run by another organization. WCR may offer general guidance but may not operate this trial, have access to its team or be able to enroll you.
Source: ClinicalTrials.gov API v2. Information is submitted by sponsors and investigators. NLM does not approve the safety or science of all listed studies. Registry disclaimer.
Retrieved: Nov 12, 2026 · Last registry update: Nov 10, 2026
